Navigation Links
Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results

SAINT PAUL, Minn., Dec. 16, 2011 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today reported financial results for its fourth quarter and fiscal year ended October 31, 2011.

Fourth Quarter Highlights:

  • Revenues of $8.4 million comparable to the fourth quarter of 2010, sequentially up 22% from the third quarter;
  • Service revenue improved 33% to $1.2 million, compared to $888,000 in last year's fourth quarter;
  • GPO (group purchasing organization) revenue during the fourth quarter increased 146% to $1.6 million, compared to $650,000 in the comparable quarter;
  • Gross margin for the fourth quarter remained solid at 56.5%;
  • International sales increased to $1.6 million, a 12% increase over the prior year's fourth quarter; and
  • Strong balance sheet with $9.2 million in cash and investments and no long-term debt.
  • Angeion reported revenue of $8.4 million compared to $8.5 million in the fourth quarter of fiscal 2010. Angeion reported net income of $391,000, or $0.10 per diluted share, versus net income of $410,000, or $0.10 per diluted share, in the comparable quarter last year. Sequentially, revenues in the fourth quarter increased 22% from $6.8 million in the third quarter of fiscal 2011.

    Gross margin for the quarter improved to 56.5% compared to the 56.1% gross margin in the fourth quarter of fiscal year 2010. General and administrative expenses in the fourth quarter of fiscal 2011 decreased 13.4% primarily due to the absence of severance and related one-time expenses in the fourth quarter of fiscal 2010. Management will continue to examine operating expenses going forward to maintain profitability. Sales and marketing expenses decreased 3.4% compared to the fourth quarter of fiscal 2010 while research and development costs increased 33.2% as management dedicated additional resources to advance software and hardware development initiatives to enhance current product offerings and develop future new products.

    Gregg O. Lehman, Ph.D., president and chief executive officer of Angeion Corporation commented, "The results of the fourth quarter are gratifying. On a sequential basis, total revenues increased 22% and service revenues increased 33% year-over-year, as we continue to emphasize to our customers the importance of maintaining the highest level of efficiency possible. We are particularly pleased with the traction that we are beginning to gain with our GPO (group purchasing organization) partners. Sales from that channel increased 146%, representing 19% of total sales for the quarter versus 8% of total sales in last year's comparable quarter. We believe that in the coming years GPO channel sales will be a positive contributor in smoothing out some of the 'lumpiness' that has historically characterized our revenue stream over the course of our fiscal year. We achieved measurable progress during the quarter that made a meaningful contribution to the results of the fiscal year. We look forward to maintaining that trend in the new fiscal year as we work to rebrand the company as a leading-edge medical technology provider."

    Fiscal Year 2011 Financial Results
    For the fiscal year ended October 31, 2011, Angeion reported revenues of $29.1 million, as compared to revenues of $29.0 million for the prior year. Angeion reported a net loss of $152,000, or $(0.04) per diluted share versus a net loss of $849,000, or $(0.21) per diluted share in the prior year. Financial results for the year were impacted by severance charges and associated legal and consulting fees attributable to the departure of executive officers. Severance and related one-time items incurred in fiscal 2011 totaled approximately $614,000, or $0.16 per diluted share, compared to one-time items of approximately $450,000, or $0.11 per diluted share in fiscal 2010.

    Gross margin for the fiscal year improved to 56.9% compared to the 54.4% gross margin in fiscal year 2010 primarily due to lower factory and technical service costs. General and administrative expenses for the fiscal year decreased 4.8% versus the prior year as a result of administrative staff changes. Sales and marketing expenses increased 2.9% compared to fiscal 2010 while research and development costs increased 1.5% for the year.

    Regarding fiscal year 2011, Dr. Lehman said, "We are pleased with the progress that has been achieved in the two quarters since our new management team was installed.  Our initial focus has been to stabilize the business and to manage costs. While revenues for the year were essentially flat, our cost of revenues decreased 5.5% and our gross margin for the year increased 255 basis points. Service revenues for the year increased 18.3% to $4.1 million, the highest in the history of the company, and we cut general and administrative expenses by approximately 5%. Excluding the severance and related one-time items, we were able to achieve profitability for the full year, which sets the stage for a productive fiscal 2012."

    Dr. Lehman continued, "We move into the new fiscal year with a strong cash position and no short or long-term debt. We also have a net operating loss carry forward of approximately $15.9 million of which use is contingent upon the Company's future profitability and is fully reserved. More importantly, we are executing on a new strategic plan that includes upgrading our current product lines, developing new products, both internally and with strategic partners, and entering new markets where our products are ideally suited to drive improved patient outcomes and cost efficiencies. We have identified the primary care, cardiology and the sleep disorder markets as potential opportunities for future entry. These are large and growing market segments that we believe will benefit from our current and new technology offerings, and that will guide our discussions with future potential partners. We are excited with the many opportunities ahead for the 'new' Angeion."

    Balance Sheet
    As of October 31, 2011, the Company ended fiscal 2011 with cash, equivalents and short term investments totaling $9.2 million, no long-term debt and shareholders' equity of $14.3 million. For the year, the Company repurchased a total of approximately 46,000 shares of Angeion common stock in the open market for $198,000. Under the current stock repurchase program, the Company has the authorization to purchase an additional $2.8 million worth of stock.

    Conference Call
    The Company has scheduled a conference call for December 16, 2011 at 12:00 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2011.

    Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10007564, through December 21, 2011. A webcast replay of the conference call will be accessible on the Company's website at for 30 days.

    About Angeion Corporation
    Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ( and New Leaf ( brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit

    Forward Looking Statements
    Press releases and other statements by Angeion may contain forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "plan," "will," "target," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (4) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (5) our success in executing our new strategic plan, developing new products and entering new markets; (6) our ability to complete our  software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (7) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (8) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (9) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures and (13) our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2010.Contact:

    Robert M. Wolf

    Joe Dorame, Robert Blum, Joe Diaz 

    Angeion Corporation

    Lytham Partners, LLC 

    Chief Financial Officer

    (602) 889-9700 

    Consolidated Balance Sheets
    October 31, 2011 and October 31, 2010
    (In thousands except share and per share data)  October 31,2011 October 31,2010ASSETS 


     Current Assets: 


     Cash and cash equivalents

    $   8,461


    $   6,943Short-term investments



    2,721Accounts receivable, net of allowance for doubtful accounts of $96 and $100, respectively



    5,221Inventories, net of obsolescence reserve of $431 and $599, respectively



    3,697Prepaid expenses and other current assets



    270Total Current Assets






     Noncurrent investments



    722Property and equipment, net of accumulated depreciation of $3,735 and $3,649, respectively



    528Intangible assets, net



    1,279Total Assets$ 20,772 $ 21,381 





     Current Liabilities: 


     Accounts payable

    $   2,022


    $   1,951Employee compensation



    2,115Deferred income



    1,522Warranty reserve



    175Other current liabilities and accrued expenses



    408Total Current Liabilities






     Long-term Liabilities: 


     Long-term deferred income and other



    873Total Liabilities6,453


    7,044Commitments and Contingencies-


    -Shareholders' Equity: 


     Common Stock, $0.10 par value, authorized 25,000,000 shares,3,905,948 and 3,862,113 shares issued and 3,778,796 and3,747,454 shares outstanding at 2011 and 2010, respectively



    375Undesignated shares, authorized 5,000,000 shares, no shares issued and outstanding



    -Additional paid-in capital



    20,486Accumulated deficit



    (6,531)Accumulated other comprehensive income



    7Total Shareholders' Equity14,319


    14,337Total Liabilities and Shareholders' Equity$ 20,772 $ 21,381 



    Consolidated Statements of Operations
    (In thousands except share and per share data)  

     Three Months EndedOctober 31, Year EndedOctober 31, 

     2011 2010 2011 2010Revenues 







     Equipment, supplies and accessories






    $   24,904


    $   25,522Service revenues
















    29,041Cost of revenues 







     Cost of equipment, supplies and accessories








    11,647Cost of service revenue
























     Gross margin 















     Operating expenses: 







     Selling and marketing








    8,067General and administrative








    4,514Research and development








    3,606Amortization of intangibles
























     Operating income (loss)  







    (816)Interest income, net















     Income (loss) before income taxes 







    (808)Provision for income taxes
















     Net income (loss) 















     Income (loss) per share: 








    $  0.10


    $  0.10


    $  (0.04)


    $  (0.21)Diluted 

    $  0.10


    $  0.10


    $  (0.04)


    $  (0.21) 








     Weighted average common shares outstanding: 





















    Consolidated Statements of Cash Flows
    (In thousands)  

     Year Ended October 31, 

     2011 2010Cash flows from operating activities: 



     Net loss


    $   (152)


    $   (849)Adjustments to reconcile net loss to net cash provided by operating activities:












    420Stock-based compensation




    712(Decrease) increase in allowance for doubtful accounts




    (10)(Decrease) increase in inventory obsolescence reserve




    (46)Loss on disposal of equipment and intangibles




    -Change in operating assets and liabilities:




     Accounts receivable








    757Prepaid expenses and other current assets




    (27)Accounts payable




    180Employee compensation




    740Deferred income




    64Warranty reserve




    32Other current liabilities and accrued expenses




    63Net cash (used in) provided by operating activities








     Cash flows from investing activities: 



     Purchases of investments




    (4,915)Sales of investments




    1,479Purchases of property and equipment and intangible assets




    (438)Net cash provided by (used in) investing activities








     Cash flows used in financing activities: 



     Proceeds from issuance of common stock under employee stock purchase plan




    17Proceeds from the exercise of stock options




    6Repurchase of common stock




    (2,024)Repurchase of common stock upon vesting of restricted stock grants




    (86)Net cash used in financing activities








     Net increase (decrease) in cash and cash equivalents 



    (4,276)Cash and cash equivalents at beginning of period 



    11,219Cash and cash equivalents at end of period 

    $  8,461


    $  6,943 

    Cash paid for taxes 









    SOURCE Angeion Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
    2. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
    3. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
    4. GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation
    5. Sigma-Aldrich Corporation to Present at Upcoming Investor Conference
    6. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
    7. Leatt Corporation Announces 2011 Annual Shareholders Meeting
    8. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
    9. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
    10. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
    11. Ansell Limited Acquires a Minority Share in Yulex Corporation
    Post Your Comments:
    (Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
    (Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
    (Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
    (Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
    (Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
    (Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
    Breaking Medicine News(10 mins):